Leverage is modest with a debt-to-equity ratio of 0.17 and $13.2M of debt in 2026Q2, but the asset base is cash-dominated with $117.1M of $133.5M total assets, and $28.1M of deferred revenue represents collaboration obligations rather than free cash.
ProQR Therapeutics N.V. (PRQR) balance sheet — 13-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Total Current Assets | 121.58M | 117.59M | 159.31M | 133.65M | 164.85M | 217.75M | 97.91M | 128.71M | 123.88M | 60.71M | 65.41M | 97.77M | 113.9M | 4.26M |
| Cash & Short-Term Investments | 117.08M | 108.53M | 154.71M | 131.37M | 101.15M | 213.25M | 92.79M | 125.66M | 120.69M | 57.76M | 62.44M | 94.86M | 112.74M | 4.13M |
| Cash Only | 117.08M | 108.53M | 154.71M | 131.37M | 101.15M | 213.25M | 92.79M | 125.66M | 120.69M | 57.76M | 62.44M | 94.86M | 112.74M | 4.13M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.86M | 5.97M | 2.1M | 1.4M | 61.09M | 935.91K | 978.84K | 1.34M | 2.45M | 563.17K | 1.65M | 1.5M | 426K | 130K |
| Days Sales Outstanding | 68.55 | 142.7 | 40.52 | 78.49 | 6.2K | 255.89 | 347.21 | 252.23 | 180.88 | -134.44 | 264.02 | 58.32 | 496.77 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 547K | 327K | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | 413.49 | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.16M | 0 |
| Total Non-Current Assets | 11.92M | 14.83M | 14.61M | 18.67M | 17.99M | 20.58M | 22.89M | 3.22M | 2.13M | 3.05M | 3.72M | 2.34M | 1.35M | 243K |
| Property, Plant & Equipment | 11.92M | 14.83M | 14.61M | 18.67M | 17.33M | 19.86M | 22.76M | 2.74M | 2.13M | 3.01M | 3.63M | 2.2M | 1.19M | 204K |
| Fixed Asset Turnover | 1.33x | 1.03x | 1.29x | 0.35x | 0.21x | 0.07x | 0.05x | 0.71x | 2.32x | -0.51x | 0.63x | 4.28x | 0.26x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46.83K | 94.93K | 141K | 163K | 39K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 662.76K | 715.3K | 130.92K | 481.55K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 133.5M | 132.43M | 173.92M | 152.31M | 182.84M | 238.33M | 120.8M | 131.93M | 126.01M | 63.77M | 69.13M | 100.11M | 115.25M | 4.5M |
| Asset Turnover | 0.14x | 0.12x | 0.11x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.04x | -0.02x | 0.03x | 0.09x | 0.00x | - |
| Asset Growth % | -49.01% | -23.86% | 14.19% | -16.7% | -23.28% | 97.3% | -8.44% | 4.7% | 97.61% | -7.76% | -30.94% | -13.14% | 2458.77% | - |
| Total Current Liabilities | 34.86M | 38.1M | 40.28M | 37.78M | 22.4M | 31.38M | 12.6M | 12.34M | 9.33M | 10.2M | 7.08M | 5.49M | 3.01M | 3.6M |
| Accounts Payable | 0 | 349.99K | 16.57K | 1.7M | 418.36K | 217.21K | 270.4K | 499.51K | 154.32K | 655.64K | 345.96K | 885K | 1.25M | 745K |
| Days Payables Outstanding | 59.34 | 49.2 | - | - | - | - | - | 1.56 | 57.27 | 238.99 | 98.53 | 669 | - | - |
| Short-Term Debt | 4.5M | 5.22M | 4.62M | 1.78M | 4.15M | 7.17M | 2.93M | 955.25K | 0 | 2.35M | 0 | 0 | 0 | 2.51M |
| Deferred Revenue (Current) | 81.28M | 20.61M | 22.72M | 22.72M | 6.02M | 5.82M | 856.49K | 798.1K | 623.02K | 416.68K | 0 | 144K | 468K | 46K |
| Other Current Liabilities | 12.72M | 11.92M | 12.92M | 11.58M | 11.81M | 18.18M | 8.54M | 10.01M | 8.54M | 6.77M | 6.72M | 4.21M | 1.39M | 279K |
| Current Ratio | 3.49x | 3.09x | 3.95x | 3.54x | 7.36x | 6.94x | 7.77x | 10.43x | 13.28x | 5.95x | 9.24x | 17.82x | 37.79x | 1.18x |
| Quick Ratio | 3.49x | 3.09x | 3.95x | 3.54x | 7.36x | 6.94x | 7.77x | 10.43x | 13.28x | 5.95x | 9.24x | 17.72x | 37.68x | 1.18x |
| Cash Conversion Cycle | 9.2 | - | - | - | - | - | - | - | - | - | - | -197.19 | - | - |
| Total Non-Current Liabilities | 19.19M | 36.34M | 41.93M | 68.81M | 89.28M | 78.19M | 39.01M | 14.27M | 10.73M | 6.35M | 6.01M | 4.82M | 2.83M | 991K |
| Long-Term Debt | 0 | 0 | 0 | 4.74M | 4.56M | 44.71M | 19.81M | 14.27M | 8.04M | 6.35M | 4.85M | 4.82M | 2.81M | 943K |
| Capital Lease Obligations | 42.12M | 11.21M | 11.46M | 15.28M | 14.74M | 16.77M | 19.2M | 0 | 0 | 0 | 0 | 0 | 15K | 48K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.69M | 0 | 1.16M | 0 | 0 | 0 |
| Total Liabilities | 54.05M | 74.44M | 82.22M | 106.59M | 111.68M | 109.57M | 51.61M | 26.61M | 20.06M | 16.54M | 13.09M | 10.31M | 5.84M | 4.59M |
| Total Debt | 13.19M | 16.43M | 16.08M | 21.8M | 23.45M | 68.66M | 41.94M | 15.22M | 8.04M | 8.7M | 4.85M | 4.84M | 2.86M | 3.54M |
| Net Debt | -103.89M | -92.1M | -138.63M | -109.57M | -77.7M | -144.6M | -50.85M | -110.44M | -112.65M | -49.06M | -57.59M | -90.03M | -109.87M | -589K |
| Debt / Equity | 0.17x | 0.28x | 0.18x | 0.48x | 0.33x | 0.53x | 0.61x | 0.14x | 0.08x | 0.18x | 0.09x | 0.05x | 0.03x | - |
| Debt / EBITDA | -0.33x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.57x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -45.75x | -24.96x | -22.12x | -11.50x | -16.82x | -24.90x | -159.14x | -44.78x | -67.95x | -69.16x | 93.17x | 80.65x | -84.61x |
| Total Equity | 79.44M | 57.99M | 91.7M | 45.72M | 71.17M | 128.76M | 69.19M | 105.33M | 105.95M | 47.22M | 56.05M | 89.8M | 109.4M | -89K |
| Equity Growth % | 55.59% | -36.77% | 100.57% | -35.75% | -44.73% | 86.11% | -34.31% | -0.59% | 124.37% | -15.74% | -37.59% | -17.92% | - | - |
| Book Value per Share | 0.72 | 0.55 | 1.12 | 0.56 | 0.99 | 2.01 | 1.38 | 2.57 | 3.11 | 1.86 | 2.40 | 3.85 | 4.94 | -0.00 |
| Total Shareholders' Equity | 79.44M | 57.99M | 91.7M | 45.72M | 71.58M | 129.45M | 69.85M | 105.88M | 106.22M | 47.27M | 56.05M | 89.8M | 109.4M | -89K |
| Common Stock | 5.74M | 5.06M | 4.46M | 3.72M | 3.6M | 3.41M | 2.65M | 2.42M | 1.97M | 1.75M | 985.14K | 934K | 934K | 59K |
| Retained Earnings | -487.21M | -549.06M | -442.32M | -442.8M | -404.6M | -361.37M | -315.37M | -237.68M | -177.69M | -143.34M | -79.88M | -36.63M | -15.8M | -3.67M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 29.49M | 33.7M | 28.58M | 28.69M | 32.3M | 34.46M | 29.26M | 18.75M | 12.45M | 10.22M | 4.58M | 1K | 687K | 41K |
| Minority Interest | 0 | 0 | 0 | 0 | -409.82K | -686.87K | -666.83K | -556.76K | -262.92K | -45.63K | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying PRQR stock.
As of 2025, ProQR Therapeutics N.V. (PRQR) had total assets of $132.4M including $117.6M in current assets.
ProQR Therapeutics N.V. (PRQR) carries total debt of $16.4M, offset by $108.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ProQR Therapeutics N.V. (PRQR) has total shareholders' equity (book value) of $58.0M ($0.55 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ProQR Therapeutics N.V. (PRQR) reported a current ratio of 3.09x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Shrinking cash reserves versus burn
Balance Sheet Shrinking Since Early 2024
According to the reported balance sheet, PRQR's total assets fell from $173.9M in 2024Q4 to $133.5M in 2026Q2, a contraction of roughly 23 percent that tracks cash depletion rather than asset growth.
The decline in total assets is driven overwhelmingly by the drop in cash from $154.7M to $117.1M over the period, which suggests the balance sheet is being consumed by operating burn instead of being rebuilt through new capital. Equity has recovered from $27.9M in 2024Q3 to $79.4M in 2026Q2, but this improvement appears to reflect financing or revaluation effects rather than earnings, given the accumulated deficit of roughly -$487M. Investors should monitor whether the equity rebound reflects durable capital raising or simply the timing of liability reductions.
Liquidity Strong Yet Finite Runway
Based on reported figures, PRQR held $117.1M in cash against a current ratio of 3.49 in 2026Q2, a buffer that looks comfortable on paper but is being drawn down by sustained cash outflows.
A current ratio above 3 indicates short-term obligations are well covered, and current liabilities of roughly $54M appear manageable against the cash balance. However, with free cash flow negative in every reported quarter and operating cash outflows of roughly $12M in the latest quarter, the implied runway is finite and warrants further investigation as to how long current cash supports operations. The liquidity position is therefore adequate in the near term but is not self-sustaining.
Low Leverage Reflects Limited Borrowing
As reported in financial statements, PRQR's debt of $13.2M against equity of $79.4M produced a debt-to-equity ratio of 0.17 in 2026Q2, down from 0.63 in 2024Q3.
Leverage has moved lower, but the reduction reflects both debt paydown and a larger equity base rather than a deliberate deleveraging strategy visible in the data. Debt of roughly $13M is modest relative to total assets of $133.5M, which suggests financing risk is limited. The more relevant constraint is equity funding dependence, since the company's operating losses, not its debt load, appear to be the binding pressure on the balance sheet.
Asset Base Is Cash Dominated
Based on EDBL's reported figures, PRQR's assets are concentrated in cash, with $117.1M of $133.5M total assets held as cash in 2026Q2, and property and equipment of only $11.9M.
A cash share near 88 percent indicates an asset-light, cash-dependent structure with no goodwill and modest fixed assets, consistent with a clinical-stage biotechnology model. This profile offers flexibility but also means asset value is largely a function of the cash balance, which is declining. PPE has drifted down from $18.1M in 2024Q1 to $11.9M, a pattern that may indicate reduced investment in infrastructure as spending is constrained.
Deferred Revenue Masks Cash Erosion
Deferred revenue of $28.1M in 2026Q2 may appear to cushion the balance sheet, but it is a collaboration liability that is unwound through future revenue recognition rather than representing cash on hand.
Deferred revenue has fallen from $66.8M in 2024Q1 to $28.1M, and its decline may reflect recognition of prior upfront payments rather than new cash inflows. Because this liability is typically settled through performance obligations instead of repayment, it does not represent a cash claim, yet its shrinkage reduces future revenue visibility. Headline liquidity metrics may therefore overstate the company's underlying financial flexibility if the revenue pipeline is not replenished.